CNS penetration of the opioid glycopeptide MMP-2200

A microdialysis study

Omar S. Mabrouk, Torsten Falk, Scott J Sherman, Robert T. Kennedy, Robin L Polt

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Endogenous opioid peptides enkephalin and dynorphin are major co-transmitters of striatofugal pathways of the basal ganglia. They are involved in the genesis of levodopa-induced dyskinesia and in the modulation of direct and indirect striatal output pathways that are disrupted in Parkinson's disease. One pharmacologic approach is to develop synthetic glycopeptides closely resembling endogenous peptides to restore their normal functions. Glycosylation promotes penetration of the blood-brain barrier. We investigated CNS penetration of the opioid glycopeptide MMP-2200, a mixed δ/μ-agonist based on leu-enkephalin, as measured by in vivo microdialysis and subsequent mass spectrometric analysis in awake, freely moving rats. The glycopeptide (10. mg/kg) reaches the dorsolateral striatum (DLS) rapidly after systemic (i.p.) administration and is stably detectable for the duration of the experiment (80. min). The detected level at the end of the experiment (around 250. pM) is about 10-fold higher than the level of the endogenous leu-enkephalin, measured simultaneously. This is one of the first studies to directly prove that glycosylation of an endogenous opioid peptide leads to excellent blood-brain barrier penetration after systemic injection, and explains robust behavioral effects seen in previous studies by measuring how much glycopeptide reaches the target structure, in this case the DLS.

Original languageEnglish (US)
Pages (from-to)99-103
Number of pages5
JournalNeuroscience Letters
Volume531
Issue number2
DOIs
StatePublished - Dec 7 2012

Fingerprint

Glycopeptides
Microdialysis
Opioid Analgesics
Leucine Enkephalin
Opioid Peptides
Blood-Brain Barrier
Glycosylation
Corpus Striatum
Dynorphins
Enkephalins
Dyskinesias
Levodopa
Basal Ganglia
Parkinson Disease
Peptides
Injections
tyrosyl-glycyl-phenylalanyl-leucyl-(O-lactosyl)serinamide

Keywords

  • Glycopeptide, Blood-brain barrier penetration
  • Leu-enkephalin
  • Mass spectrometry
  • Striatum

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

CNS penetration of the opioid glycopeptide MMP-2200 : A microdialysis study. / Mabrouk, Omar S.; Falk, Torsten; Sherman, Scott J; Kennedy, Robert T.; Polt, Robin L.

In: Neuroscience Letters, Vol. 531, No. 2, 07.12.2012, p. 99-103.

Research output: Contribution to journalArticle

@article{e5c0f9aa4b394f7797d8131ccdd184a9,
title = "CNS penetration of the opioid glycopeptide MMP-2200: A microdialysis study",
abstract = "Endogenous opioid peptides enkephalin and dynorphin are major co-transmitters of striatofugal pathways of the basal ganglia. They are involved in the genesis of levodopa-induced dyskinesia and in the modulation of direct and indirect striatal output pathways that are disrupted in Parkinson's disease. One pharmacologic approach is to develop synthetic glycopeptides closely resembling endogenous peptides to restore their normal functions. Glycosylation promotes penetration of the blood-brain barrier. We investigated CNS penetration of the opioid glycopeptide MMP-2200, a mixed δ/μ-agonist based on leu-enkephalin, as measured by in vivo microdialysis and subsequent mass spectrometric analysis in awake, freely moving rats. The glycopeptide (10. mg/kg) reaches the dorsolateral striatum (DLS) rapidly after systemic (i.p.) administration and is stably detectable for the duration of the experiment (80. min). The detected level at the end of the experiment (around 250. pM) is about 10-fold higher than the level of the endogenous leu-enkephalin, measured simultaneously. This is one of the first studies to directly prove that glycosylation of an endogenous opioid peptide leads to excellent blood-brain barrier penetration after systemic injection, and explains robust behavioral effects seen in previous studies by measuring how much glycopeptide reaches the target structure, in this case the DLS.",
keywords = "Glycopeptide, Blood-brain barrier penetration, Leu-enkephalin, Mass spectrometry, Striatum",
author = "Mabrouk, {Omar S.} and Torsten Falk and Sherman, {Scott J} and Kennedy, {Robert T.} and Polt, {Robin L}",
year = "2012",
month = "12",
day = "7",
doi = "10.1016/j.neulet.2012.10.029",
language = "English (US)",
volume = "531",
pages = "99--103",
journal = "Neuroscience Letters",
issn = "0304-3940",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - CNS penetration of the opioid glycopeptide MMP-2200

T2 - A microdialysis study

AU - Mabrouk, Omar S.

AU - Falk, Torsten

AU - Sherman, Scott J

AU - Kennedy, Robert T.

AU - Polt, Robin L

PY - 2012/12/7

Y1 - 2012/12/7

N2 - Endogenous opioid peptides enkephalin and dynorphin are major co-transmitters of striatofugal pathways of the basal ganglia. They are involved in the genesis of levodopa-induced dyskinesia and in the modulation of direct and indirect striatal output pathways that are disrupted in Parkinson's disease. One pharmacologic approach is to develop synthetic glycopeptides closely resembling endogenous peptides to restore their normal functions. Glycosylation promotes penetration of the blood-brain barrier. We investigated CNS penetration of the opioid glycopeptide MMP-2200, a mixed δ/μ-agonist based on leu-enkephalin, as measured by in vivo microdialysis and subsequent mass spectrometric analysis in awake, freely moving rats. The glycopeptide (10. mg/kg) reaches the dorsolateral striatum (DLS) rapidly after systemic (i.p.) administration and is stably detectable for the duration of the experiment (80. min). The detected level at the end of the experiment (around 250. pM) is about 10-fold higher than the level of the endogenous leu-enkephalin, measured simultaneously. This is one of the first studies to directly prove that glycosylation of an endogenous opioid peptide leads to excellent blood-brain barrier penetration after systemic injection, and explains robust behavioral effects seen in previous studies by measuring how much glycopeptide reaches the target structure, in this case the DLS.

AB - Endogenous opioid peptides enkephalin and dynorphin are major co-transmitters of striatofugal pathways of the basal ganglia. They are involved in the genesis of levodopa-induced dyskinesia and in the modulation of direct and indirect striatal output pathways that are disrupted in Parkinson's disease. One pharmacologic approach is to develop synthetic glycopeptides closely resembling endogenous peptides to restore their normal functions. Glycosylation promotes penetration of the blood-brain barrier. We investigated CNS penetration of the opioid glycopeptide MMP-2200, a mixed δ/μ-agonist based on leu-enkephalin, as measured by in vivo microdialysis and subsequent mass spectrometric analysis in awake, freely moving rats. The glycopeptide (10. mg/kg) reaches the dorsolateral striatum (DLS) rapidly after systemic (i.p.) administration and is stably detectable for the duration of the experiment (80. min). The detected level at the end of the experiment (around 250. pM) is about 10-fold higher than the level of the endogenous leu-enkephalin, measured simultaneously. This is one of the first studies to directly prove that glycosylation of an endogenous opioid peptide leads to excellent blood-brain barrier penetration after systemic injection, and explains robust behavioral effects seen in previous studies by measuring how much glycopeptide reaches the target structure, in this case the DLS.

KW - Glycopeptide, Blood-brain barrier penetration

KW - Leu-enkephalin

KW - Mass spectrometry

KW - Striatum

UR - http://www.scopus.com/inward/record.url?scp=84870435002&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870435002&partnerID=8YFLogxK

U2 - 10.1016/j.neulet.2012.10.029

DO - 10.1016/j.neulet.2012.10.029

M3 - Article

VL - 531

SP - 99

EP - 103

JO - Neuroscience Letters

JF - Neuroscience Letters

SN - 0304-3940

IS - 2

ER -